Publications by authors named "Zerr D"

Background: Pediatric respiratory syncytial virus (RSV)-related acute lower respiratory tract infection (LRTI) commonly requires hospitalization. The Clinical Progression Scale Pediatrics (CPS-Ped) measures level of respiratory support and degree of hypoxia across a range of disease severity, but it has not been applied in infants hospitalized with severe RSV-LRTI.

Methods: We analyzed data from a prospective surveillance registry of infants hospitalized for RSV-related complications across 39 U.

View Article and Find Full Text PDF

In 2011, the Society for Healthcare Epidemiology of America (SHEA) and Ronald McDonald House Charities® (RMHC®) established a formal collaboration to develop the first IPC guideline. Both organizations agreed that RMH programs staff and other organizations operating similar programs would benefit from a standardized approach. In 2023, the collaboration was re-established to revise and update the original IPC guideline.

View Article and Find Full Text PDF

To determine if healthcare-associated (HA)-respiratory syncytial virus (RSV) is associated with worse outcomes, this multicenter cohort study studied 26 children with HA-RSV and 78 matched non-HA-RSV patients of whom 58% and 55%, respectively, had ≥2 comorbidities. Overall, 39% of HA-RSV versus 18% of non-HA-RSV patients required respiratory support escalation (adjusted odds ratio (aOR) 5.1, CI95 1.

View Article and Find Full Text PDF

Background: The burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in asymptomatic children was initially presumed to be high, which influenced hospital, school and childcare policies. Before vaccines were widely available, some hospitals implemented universal preprocedural SARS-CoV-2 polymerase chain reaction testing on asymptomatic patients. Understanding SARS-CoV-2 prevalence in asymptomatic children is needed to illuminate the diversity of viral characteristics and inform policies implemented during future pandemics.

View Article and Find Full Text PDF
Article Synopsis
  • Rotavirus was a major cause of gastroenteritis in US children until the introduction of vaccines in 2006, which led to significant reductions in severe cases.
  • A study from 2009 to 2022 analyzed vaccine effectiveness (VE) using data from children with acute gastroenteritis, revealing a 78% effectiveness rate against severe rotavirus-related medical visits.
  • The effectiveness varied by severity of disease, showing 94% effectiveness against very severe cases, with younger children benefiting the most from vaccination.
View Article and Find Full Text PDF
Article Synopsis
  • - Human herpesvirus-6B (HHV-6B) reactivation is linked to higher rates of non-relapse mortality (NRM) and overall mortality (OM) in patients undergoing allogeneic hematopoietic stem cell transplants (HCT).
  • - A systematic review and meta-analysis showed a significant association between HHV-6B presence and increased NRM (effect size: 1.84) and OM (effect size: 1.37) after HCT, with NRM results being consistent across studies.
  • - The findings suggest that detecting HHV-6B can be critical for patient outcomes following HCT, highlighting the need for further randomized trials to explore the potential benefits of preventing
View Article and Find Full Text PDF

Importance: The Centers for Disease Control and Prevention plans to introduce hospital-onset bacteremia (HOB) as a health care-associated infection measure. The epidemiology and clinical characteristics of HOB among infants admitted to the neonatal intensive care unit (NICU) are unknown.

Objective: To estimate the rate of HOB among infants admitted to the NICU, measure the association of HOB risk with birth weight group and postnatal age, and estimate HOB-attributable mortality.

View Article and Find Full Text PDF

Objectives: Multiple viral respiratory epidemics occurred concurrently in 2022 but their true extent is unclear. To aid future surge planning efforts, we compared epidemiology and resource utilization with prepandemic viral respiratory seasons in 38 US children's hospitals.

Methods: We performed a serial cross-sectional study from October 2017 to March 2023.

View Article and Find Full Text PDF

Special pathogens are broadly defined as highly transmissible organisms capable of causing severe disease in humans. Children's hospital healthcare personnel (HCP) should be prepared to identify patients possibly infected with a special pathogen, isolate the patient to minimize transmission, and inform key infection prevention, clinical, and public health stakeholders. Effective preparedness requires resources and practice with attention to education, policies and procedures, drills and training, and supplies.

View Article and Find Full Text PDF

Health equity gaps persist across minoritized groups due to systems of oppression affecting health-related social needs such as access to transportation, education and literacy, or food and housing security. Consequently, disparities in the prevalence of multidrug-resistant infections, infectious disease outcomes, and inappropriate antimicrobial use have been reported across minoritized populations. The Joint Commission and Centers for Medicare and Medicaid Services (CMS) have formally acknowledged the importance of integrating health equity-focused initiatives into existing hospital quality improvement (QI) programs.

View Article and Find Full Text PDF
Article Synopsis
  • Human herpesvirus 6B (HHV-6B) has been linked to cases of reactivation and disease following chimeric antigen receptor (CAR) T-cell therapy (CARTx), raising management concerns for patients and products.
  • A study found that of 89 participants undergoing CARTx, 6% experienced reactivation, but the levels of HHV-6B were low and did not necessitate treatment.
  • Further analysis of 626 patients revealed an even lower incidence of potential HHV-6B encephalitis, suggesting that HHV-6B reactivation is rare and ongoing monitoring may not be needed.
View Article and Find Full Text PDF

Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S.

View Article and Find Full Text PDF
Article Synopsis
  • Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants in the U.S., prompting the CDC to recommend nirsevimab, a monoclonal antibody, for infants under 8 months and at-risk children aged 8-19 months to prevent severe infection during their first RSV season.
  • In clinical trials, nirsevimab showed an 81% efficacy rate for preventing RSV-related hospitalizations, while a recent analysis during RSV season (October 2023-February 2024) reported a 90% effectiveness among treated infants.
  • Despite limited numbers of treated infants, the findings support ongoing recommendations for nirsevimab and emphasize the importance of maternal vaccination or direct nirsevimab administration
View Article and Find Full Text PDF

We sought to evaluate whether children hospitalized with acute respiratory infections experienced differences in antibiotic use by race and ethnicity. We found that likelihood of broad-spectrum antibiotic receipt differed across racial and ethnic groups. Future work should confirm this finding, evaluate causes, and ensure equitable antibiotic use.

View Article and Find Full Text PDF

Infectious diseases (ID) research is vital for global public health, typically led by physician-scientists. This Perspective addresses challenges in the ID workforce and suggests solutions. Physician-scientists have made key discoveries that have significantly impacted human health.

View Article and Find Full Text PDF

Limited understanding of the immunopathogenesis of human herpesvirus 6B (HHV-6B) has prevented its acceptance as a pulmonary pathogen after hematopoietic cell transplant (HCT). In this prospective multicenter study of patients undergoing bronchoalveolar lavage (BAL) for pneumonia after allogeneic HCT, we test blood and BAL fluid (BALF) for HHV-6B DNA and mRNA transcripts associated with lytic infection and perform RNA-seq on paired blood. Among 116 participants, HHV-6B DNA is detected in 37% of BALs, 49% of which also have HHV-6B mRNA detection.

View Article and Find Full Text PDF

Introduction: Evidence about the effectiveness and safety of dog visits in pediatric oncology is limited.

Method: We conducted a randomized controlled trial (n=26) of dog visits versus usual care among pediatric oncology inpatients. Psychological functioning and microbial load from hand wash samples were evaluated.

View Article and Find Full Text PDF

The COVID-19 pandemic has upended societal norms and changed the way the health risks associated with respiratory viral infections are viewed. In this commentary, the authors advocate for mindfulness of continuing areas of uncertainty along with integration of the lessons learned into hospital-based practices to prevent harm to vulnerable patients rather than reverting to suboptimal prepandemic behaviors.

View Article and Find Full Text PDF

Importance: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) and infant hospitalization worldwide.

Objective: To evaluate the characteristics and outcomes of RSV-related critical illness in US infants during peak 2022 RSV transmission.

Design, Setting, And Participants: This cross-sectional study used a public health prospective surveillance registry in 39 pediatric hospitals across 27 US states.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores the effects of letermovir on the use of anti-CMV therapy and HHV-6 incidence in allogeneic HCT patients, indicating a significant reduction in broad-spectrum antiviral use post-letermovir.
  • Analysis of 738 patients showed no significant change in the cumulative incidence of HHV-6 testing and detection between pre- and post-letermovir groups, with only minor differences in HHV-6-related conditions.
  • Overall, despite the reduced use of broad-spectrum antivirals due to letermovir implementation, HHV-6 epidemiology remained stable, with no significant associations found related to HHV-6 detection rates.
View Article and Find Full Text PDF